代谢相关脂肪性肝病已成为目前全球患病率最高的慢性肝病，与代谢综合征及相关疾病关系密切，带来了巨大的疾病负担。先前全球相关专家就非酒精性脂肪性肝病更名以及代谢相关脂肪性肝病的诊断标准达成共识，为进一步的临床研究和实践增加了信心。目前，代谢相关脂肪性肝病相关研究进展迅速，基于临床证据的观点和数据不断更新。n Hepatology International杂志发表了亚太肝脏研究协会关于代谢相关脂肪性肝病的临床诊治指南，旨在方便临床实践、提高临床研究效率，现将推荐意见翻译成中文，以期能对广大医学工作者的临床决策有所帮助。n “,”Recently, metabolic-associated fatty liver disease has become the world’s highest prevalence of chronic liver disease. Moreover, it is closely related to metabolic syndrome and related diseases, bringing a huge disease burden. Previously, the global expert consensus on renaming for non-alcoholic fatty liver disease and the diagnostic criteria for metabolic-associated fatty liver disease has increased the certainty of further clinical research and practice. Presently, the research on metabolic-associated fatty liver disease is progressing rapidly, and the opinions and data based on clinical evidence are constantly updated. Hepatology international has published the “Asian Pacific Association for the Study of liver diseases’ clinical guidelines on the management of metabolic-associated fatty liver disease” , which aims to promote clinical practice and improve the efficiency of clinical research. Here, we have translated the published recommendations into Chinese language, hoping to help most health professionals make clinical decisions.